CelSiege Biosciences Information

CelSiege Biosciences is pioneering multi-specific active immunotherapies to bring lasting control to squamous non-small cell lung cancer (sqNSCLC) and other difficult-to-treat cancers. Built on a proprietary active immunotherapy platform, CelSiege develops first-in-class biologics that target circulating growth factors to overcome resistance to standard therapies. Our lead program, CS-01, selectively depletes epidermal growth factor (EGF) to open new possibilities in squamous NSCLC — a patient population with few treatment advances in decades. Headquartered in Marseille, France, with operations in the United States, CelSiege unites a global team of scientists, clinicians, and partners dedicated to advancing a new generation of globally accessible therapeutics for patients in urgent need.